JP6487419B2 - Ｔａｆａ４化合物及び疼痛を処置するためのその使用 - Google Patents

Ｔａｆａ４化合物及び疼痛を処置するためのその使用 Download PDF

Info

Publication number
JP6487419B2
JP6487419B2 JP2016512345A JP2016512345A JP6487419B2 JP 6487419 B2 JP6487419 B2 JP 6487419B2 JP 2016512345 A JP2016512345 A JP 2016512345A JP 2016512345 A JP2016512345 A JP 2016512345A JP 6487419 B2 JP6487419 B2 JP 6487419B2
Authority
JP
Japan
Prior art keywords
pain
tafa4
neurons
protein
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016512345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519138A (ja
JP2016519138A5 (enExample
Inventor
モクリッチ，アジズ
デルフィーニ，マリー−クレール
マンティッレリ，アナベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Original Assignee
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Centre National de la Recherche Scientifique CNRS filed Critical Aix Marseille Universite
Publication of JP2016519138A publication Critical patent/JP2016519138A/ja
Publication of JP2016519138A5 publication Critical patent/JP2016519138A5/ja
Application granted granted Critical
Publication of JP6487419B2 publication Critical patent/JP6487419B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2016512345A 2013-05-06 2014-05-06 Ｔａｆａ４化合物及び疼痛を処置するためのその使用 Active JP6487419B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305592.1 2013-05-06
EP13305592.1A EP2801369A1 (en) 2013-05-06 2013-05-06 TAFA4 compounds and uses thereof for treating pain
PCT/EP2014/059247 WO2014180853A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Publications (3)

Publication Number Publication Date
JP2016519138A JP2016519138A (ja) 2016-06-30
JP2016519138A5 JP2016519138A5 (enExample) 2018-08-30
JP6487419B2 true JP6487419B2 (ja) 2019-03-20

Family

ID=48428409

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512345A Active JP6487419B2 (ja) 2013-05-06 2014-05-06 Ｔａｆａ４化合物及び疼痛を処置するためのその使用

Country Status (8)

Country Link
US (2) US9884088B2 (enExample)
EP (2) EP2801369A1 (enExample)
JP (1) JP6487419B2 (enExample)
CN (1) CN105209056B (enExample)
CA (2) CA2910652C (enExample)
DK (1) DK2994157T3 (enExample)
ES (1) ES2813629T3 (enExample)
WO (1) WO2014180853A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3270160B1 (en) * 2015-03-13 2020-03-18 Sysmex Corporation Method for detecting test substance and reagent kit used in said method
JP2021501334A (ja) * 2017-10-30 2021-01-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 電気化学的センサーを用いた、分析物の較正不要なインビボ測定
AU2019259798A1 (en) * 2018-04-24 2020-11-12 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
WO2020064907A1 (en) * 2018-09-27 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition reducing skin inflammation
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
KR20220137009A (ko) * 2020-02-04 2022-10-11 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 염증 질환을 치료하기 위한 방법 및 약제학적 조성물
KR20230010622A (ko) * 2020-02-13 2023-01-19 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Piez02-매개 통증을 감소시키는 마가르산
TWI759788B (zh) * 2020-07-08 2022-04-01 台灣粒線體應用技術股份有限公司 萃取保護液用於自細胞分離粒線體並維持粒線體活性的用途
JP2024547029A (ja) 2021-12-17 2024-12-26 タファルジー・セラピューティクス 疼痛の処置における使用のためのペプチド及び方法
CA3242979A1 (en) * 2021-12-20 2023-06-29 Amgen Inc. DLL3 LINKING PEPTIDES AND THEIR USES
US20230302207A1 (en) * 2022-03-24 2023-09-28 Baxter International Inc. Dialysis system having thermoelectric heating
AR129441A1 (es) 2022-05-25 2024-08-28 Tafalgie Therapeutics Péptidos y métodos para el tratamiento del dolor
US20260041790A1 (en) * 2022-05-31 2026-02-12 Neuracle Genetics Inc. Composition for treating retinal or macular diseases
KR20250153765A (ko) 2023-02-17 2025-10-27 나오스 인스티튜트 오브 라이프 사이언스 피부 내성 역치를 증가시킬 수 있는 생태생물학적 화합물의 선택 방법
WO2025116606A1 (ko) * 2023-11-30 2025-06-05 주식회사 뉴라클제네틱스 신규한 케모카인-유사 단백질 단편
CN121249875B (zh) * 2025-10-13 2026-03-20 上海交通大学医学院附属仁济医院 外周神经系统中的Mas相关G蛋白耦联受体D在缓解阿片类药物耐受中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090077680A1 (en) * 2000-06-12 2009-03-19 Alejandro Abuin Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same
US20090136552A1 (en) * 2004-07-30 2009-05-28 Mette Gronborg Growth factors nsg28, nsg30, and nsg32

Also Published As

Publication number Publication date
JP2016519138A (ja) 2016-06-30
US20180110829A1 (en) 2018-04-26
EP2994157B1 (en) 2020-07-01
EP2801369A1 (en) 2014-11-12
CA2910652C (en) 2024-05-28
WO2014180853A1 (en) 2014-11-13
CA2910652A1 (en) 2014-11-13
DK2994157T3 (da) 2020-08-24
ES2813629T3 (es) 2021-03-24
CN105209056A (zh) 2015-12-30
CA3235916A1 (en) 2014-11-13
EP2994157A1 (en) 2016-03-16
US9884088B2 (en) 2018-02-06
CN105209056B (zh) 2018-01-23
US20160113996A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
JP2016519138A (ja) Ｔａｆａ４化合物及び疼痛を処置するためのその使用
US11642423B2 (en) Motor neuron-specific expression vectors
Kanwar et al. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
JP2013529181A (ja) 神経障害を治療するための組成物および方法
Shi et al. Activation of TGR5 in the injured nerve site according to a prevention protocol mitigates partial sciatic nerve ligation–induced neuropathic pain by alleviating neuroinflammation
US10123983B2 (en) DNA methyltransferases for the treatment and prevention of arthritis
Wang et al. Small G-protein Rheb gates mammalian target of rapamycin signaling to regulate morphine tolerance in mice
US11969460B2 (en) Methods and compositions for treating decreased cognitive ability
CN102648977B (zh) 滤泡素抑制素样蛋白1在调节钠钾atp酶活性中的用途
Kearney et al. Rit2 silencing in dopamine neurons drives a Parkinsonian phenotype
Class et al. Patent application title: TAFA4 COMPOUNDS AND USES THEREOF FOR TREATING PAIN Inventors: Aziz Moqrich (Marseille, FR) Marie-Claire Delfini (Marseille, FR) Annabelle Mantilleri (Apt, FR)
US10947311B2 (en) VCAM-1 mediated methods and compositions for treating aging-associated impairments
US10017765B2 (en) Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
US11878012B2 (en) Compositions and methods for treating traumatic brain injury
US20250289906A1 (en) Modulation of extracellular kinase activity and function for treatment of pain and neurodegenerative/neuroimmune disease
Fuller An investigation into noxious mechanosensation, and the role of peripheral neuron subpopulations in pain
Li Neuronal Interleukin-13 (IL-13) Modulates Synaptic Physiology and Neuronal Resilience to Trauma
Rees Characterization of the 15q13. 3 Microdeletion and Its Effects on Neuronal Excitability, Astrocyte α7 Nicotinic Acetylcholine Receptor Dynamics, and Neuroinflammation
Ilaria et al. Voltage-independent GluN2A-type NMDA receptor Ca2+ signaling promotes audiogenic seizures, attentional and cognitive deficits in mice
KR20220025810A (ko) 스미스-마제니스 증후군을 치료하기 위한 방법 및 조성물
Gandhi Organisation of Glutamatergic Inputs to Central Amygdala
CN121695274A (zh) 抑郁症的治疗方法和药物组合物
O'donnell Glutamate transport affects mitochondria and calcium signaling in astrocytic processes under normal and pathological conditions
Sharma Efficacy of a novel neuronal death inhibitor in Alzheimer’s disease models
Zhang et al. Revision of PAIN-D-14-12098

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180521

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190221

R150 Certificate of patent or registration of utility model

Ref document number: 6487419

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250